GlassScriptPhysician profile
Cecilia Arango
NPI 1568768133
$13,905.12
in general payments reported to CMS, 2019-2025
42 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,292 · 2020: $1,995 · 2021: $2,675 · 2022: $2,212 · 2023: $2,341 · 2024: $1,948 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,711 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,711.09 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,920.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,005.83 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $936.50 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $871.50 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $805.47 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $787.28 | 2019-2025 | Jardiance, Tradjenta |
| Dexcom, INC. | $765.88 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $731.29 | 2019-2025 | |
| Abbvie INC. | $644.52 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $565.22 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $549.77 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $456.19 | 2019-2025 | |
| Daiichi Sankyo INC. | $416.14 | 2019-2024 | Injectafer |
| Exact Sciences Corporation | $330.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $309.82 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecilia Arango listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.